| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ImmuCell Corporation$11.02
+0.27 (+2.51%)
Market Cap
99.70 M
EPS
-0.07
P/E Ratio
-
Value Trade
155.88 K
SEC Financials
Q1 2026Dilution Risk
Revenue
10.36 M
R&D Expenses
317.69 K
Operating CF
3.57 M
Total Assets
44.11 M
Total Liabilities
14.97 M
Equity
29.14 M
-0.36 %
Week
6.58 %
1 Month
30.11 %
3 Month
80.42 %
6 Month
2.38 %
5 Year
7.95 %
All Time
Cash Data
Cash Position
6.81 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
41.57 K
52 Week Range
4.52 - 12.10
% held by Insiders
37.77 %
% held by Institutions
15.2 %
Enterprise Value
103.21 M
Total Shares
9.04 M
Short %
0.25 %
Float Shares
6.00 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-31 | Re-Tain® (novel treatment for subclinical mastitis) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-12-31 | Re-Tain® (novel treatment for subclinical mastitis) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-12-31 | Re-Tain® (novel treatment for subclinical mastitis) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
First Defense | prevention of scours (diarrhea) in newborn calves caused by rotavirus | — | 2015-02-25 | statistically significant effectiveness versus a placebo control Read More | ImmuCell Reports Results From Rotavirus Pivotal Effectiveness Study Read More | |
First Defense | prevention of scours (diarrhea) in newborn calves caused by rotavirus | — | 2015-02-25 | statistically significant effectiveness versus a placebo control Read More | ImmuCell Reports Results From Rotavirus Pivotal Effectiveness Study Read More | |
First Defense | prevention of scours (diarrhea) in newborn calves caused by rotavirus | — | 2015-02-25 | statistically significant effectiveness versus a placebo control Read More | ImmuCell Reports Results From Rotavirus Pivotal Effectiveness Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ICCC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ICCC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ICCC▲ +2.5%today
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
ImmuCell Corporation will announce its unaudited financial results for the quarter ended June 30, 2026, on August 13, 2026. A conference call is scheduled for August 14, 2026, to discuss these results. The company expects no changes to its previously disclosed preliminary sales figures, indicating consistent performance.
Read more →ICCCImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
ImmuCell Corporation reported a 12% increase in product sales for Q2 2026, totaling $7.2 million, driven by a significant rise in domestic sales. The company also noted a 21% increase in sales for the first half of 2026 compared to the same period in 2025. Despite a decline in international sales, management remains optimistic about strong demand, particularly in Canada. A conference call is scheduled for August 14, 2026, to discuss these results in detail.
Read more →ICCCManaging Passive Transfer Variability at Calf Ranches: Effects of Hyperimmunized Bovine Colostrum Supplementation on Health Outcomes
The article discusses a study on the use of hyperimmunized bovine colostrum concentrate by calf ranches to improve the health of incoming calves. It highlights the variability in calf health and the importance of optimizing management practices. The concentrate aims to boost the immune status of calves, especially those with inadequate passive transfer.
Read more →ICCCFirst Defense Technology® Field Demonstration Summary of a field demonstration to evaluate the impact of a First Defense Technology® hyperimmune E/C colostrum powder on calf health.
A large-scale calf ranch in the southwestern U.S. conducted a field demonstration to assess the effects of First Defense Technology's hyperimmune E/C colostrum powder on calf health. The study involved around 70 calves daily from various sources, focusing on metrics such as death loss and treatment events. This evaluation aims to enhance calf health management practices.
Read more →ICCCKey reasons IgY paste/gel products do not provide lasting immune support to calves.
The article discusses the ineffectiveness of IgY paste and gel products in providing lasting immune support to calves. It highlights that IgY, derived from chicken eggs, cannot be absorbed after the first day of life and lacks USDA claims for reducing scours or mortality. The author emphasizes that these products do not offer the necessary immunoglobulins that calves need for immunity.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
ImmuCell Corporation reported strong unaudited financial results for Q1 2026, with net income rising to $1.9 million, up from $1.4 million in Q1 2025. Product sales experienced a significant increase of 28.4%, driven by high demand in the cow-calf segment. The company also announced plans for capacity expansion and improved manufacturing efficiencies, despite potential revenue moderation in the upcoming quarters.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
ImmuCell Corporation plans to announce its unaudited financial results for the quarter ended March 31, 2026, on May 14, 2026. The announcement will be followed by a conference call on May 15 to review these results. There is no expected change to the preliminary sales results disclosed earlier. ImmuCell specializes in animal health biologics, particularly solutions for improving calf health.
Read more →ICCC▲ +8.7%on this news
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
ImmuCell Corporation has appointed Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, effective April 15, 2026. The company is transitioning to a smaller, 7-person Board with six independent members and the CEO. This move includes the establishment of a Strategy and Technology Committee aimed at enhancing innovation and growth in their product line, First Defense.
Read more →ICCCImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
ImmuCell Corporation reported a 28.4% increase in product sales for Q1 2026, totaling $10.4 million. Domestic sales surged by 35.7%, primarily driven by the Tri-Shield® product. However, international sales experienced a decline of 30.2%. The company is optimistic about future growth, supported by new hires in its commercial team.
Read more →ICCCImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
ImmuCell Corporation has appointed Kathy Turner to its Board of Directors, effective April 1, 2026. She replaces Steven Rosgen, who is retiring after eight years. Turner has extensive experience in global healthcare and animal health, previously serving on the Board of Elanco Animal Health. Her role includes chairing the Compensation and Stock Option Committee.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
ImmuCell Corporation reported its unaudited financial results for the year ended December 31, 2025, showing a net operating income of $1.6 million, an increase from the previous year. Despite a net loss of $1.0 million, the company noted significant improvements in gross margin and manufacturing output. The management expressed optimism about future growth driven by strategic investments and enhanced customer engagement.
Read more →ICCCHyperimmune colostrum: taking nature’s most powerful defense to the next level.
The article discusses colostral hyperimmunization, a process involving multiple vaccinations in cows to boost antigen-specific antibodies before colostrogenesis. This method significantly enhances the quality of colostrum, which is crucial for neonatal calf health. The piece also summarizes peer-reviewed studies and internal research on the benefits of this approach.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
ImmuCell Corporation will announce its unaudited financial results for the quarter and year ended December 31, 2025, on March 4, 2026. A conference call is scheduled for March 5, 2026, to discuss these results. The company expects no changes to the preliminary sales results disclosed earlier in January 2026.
Read more →ICCCSecuring the right number of replacements: Every heifer matters
The article emphasizes the importance of management expertise in handling beef-on-dairy calves, particularly in the context of a tight replacement heifer supply. It discusses the challenges of trading heifer replacements for beef-cross calves while investing in genetics. Strategies are provided to ensure optimal outcomes in calf management.
Read more →ICCCFour tips to help unlock the potential of beef-on-dairy
The article discusses the increasing strategic use of beef-on-dairy crosses in farming. It outlines four key tips for producers to maximize the potential of beef-on-dairy calves, including prioritizing calf health, selecting the right cross, capturing the best sale price, and considering various strategies. The overall sentiment is positive, highlighting the growth in calf values.
Read more →ICCCMaternity barn: setting the stage for healthy beginnings
The article discusses the importance of modernizing maternity pens in dairy operations to enhance calf health and productivity. It outlines five key strategies: ensuring cleanliness and comfort, implementing stringent biosecurity measures, creating dedicated areas for colostrum, improving overall efficiency, and utilizing monitoring technologies. These improvements can lead to better outcomes for both calves and dairy operations.
Read more →ICCCThe weather forecast for today is hot and cold: Tips for nurturing calves in fluctuating weather
The article discusses the challenges of caring for calves during extreme weather fluctuations, highlighting the significant temperature swings experienced in Wisconsin. It emphasizes the importance of monitoring calves' health and adjusting management practices, such as feeding schedules and environmental protections. The piece offers practical tips for maintaining calf health amid these conditions.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
ImmuCell Corporation reported preliminary, unaudited sales results for Q4 and full year 2025, highlighting a 1.6% decline in Q4 sales but a 4.3% increase for the full year. The company is focusing on expanding its First Defense® product line following an FDA Incomplete Letter for Re-Tain®. Manufacturing improvements and a sales force expansion are planned to support growth.
Read more →ICCCImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
ImmuCell Corporation is set to hold a conference call on January 9, 2026, to discuss its strategic shift towards the First Defense® product line and away from Re-Tain®. The call will also cover unaudited sales results for Q4 and the full year 2025. The company aims to improve cattle health and productivity with its products.
Read more →ICCCA veterinarian’s perspective on the safety of precalving scours vaccines
Veterinarian Raffael Lichdi examines the safety of precalving scours vaccines, highlighting factors such as administration routes, adjuvants, and adverse events. His insights suggest a shift in perspective regarding vaccine safety and effectiveness. The article also introduces alternative concentrated antibody products as potential solutions. This analysis encourages a reevaluation of traditional vaccine practices.
Read more →ICCCSick calves – where did I trip up?
Courtney Carter shares her experiences managing calf health on a ranch, highlighting the importance of continuous learning and effective management. The article discusses human errors in calf care, emphasizing the need for adherence to standard operating procedures (SOPs). It also offers practical advice on record-keeping and staff training to prevent health issues in calves.
Read more →ICCCImmuCell Announces Strategic Focus on First Defense After Receiving an FDA Incomplete Letter for Re-Tain
ImmuCell Corporation (Nasdaq: ICCC) has shifted focus from its Re-Tain product to its First Defense franchise after receiving an Incomplete Letter from the FDA regarding the New Animal Drug Application. The company plans to expand its First Defense sales force and manufacturing capabilities, citing significant growth potential and customer confidence. Ongoing studies for Re-Tain will continue, but further investment will be paused due to potential delays in FDA approval. A non-cash impairment write-down is also anticipated as part of this strategic change.
Read more →ICCCWinning the pathogen challenges. Experts provide a gameplan.
The article discusses strategies for preventing scours in calves, emphasizing the importance of veterinary procedures and lab testing. Experts provide insights on interpreting test results, including the differences between Elisa and PCR tests. It aims to equip producers with knowledge to identify and manage calf health issues effectively.
Read more →ICCCCalves aren’t big chicks — egg powder helps you in one way only.
The article discusses the limitations of using egg powder as a substitute for colostrum in calves. It emphasizes that while both contain antibodies, bovine colostrum is far superior for passive transfer and protecting against pathogens. The narrow benefits of egg powder are highlighted, stressing its inadequacy in preventing scours in calves.
Read more →ICCCThe cascade effect – there’s more to scours than diarrhea
The article discusses the critical first hour after a calf's birth, emphasizing its importance for immune system development. It highlights that while many calves thrive, up to 20% may suffer from neonatal diarrhea, leading to a series of health complications and economic losses for dairy producers. Experts from First Defense provide insights into prevention strategies and the broader implications of scours.
Read more →ICCC▼ -9.1%on this news
The 3 most common calf-care challenges I see on farms
The article discusses common challenges faced by calf raisers, including employee inconsistencies in feeding and treatments, over-treatment of calves, and housing issues. Sarah Eck, a Sales and Marketing Manager, shares her observations and offers solutions to these challenges. The insights aim to help producers improve their calf care practices.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
ImmuCell Corporation reported its unaudited financial results for the quarter ending September 30, 2025. The company's product sales highlighted an 8% decrease in the third quarter, though there was a 7% increase over the nine-month period compared to 2024. Notably, net income shifted to $1.8 million from a loss of $2.7 million in the same period last year, while gross margins improved significantly. Management noted sufficient inventory levels, potentially enhancing product adoption and revenue growth moving forward.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
ImmuCell Corporation will announce its unaudited financial results for Q3 2025 on November 13, 2025. Following this, a conference call is scheduled for November 14, 2025, to discuss the results. The company expects no changes to previously disclosed preliminary sales results. Investors can access additional information through the company's website.
Read more →ICCC▲ +5%on this newsshared move
ImmuCell Announces Onboarding of New CEO and Related Management Changes
ImmuCell Corporation has appointed Olivier te Boekhorst as the new President and CEO, effective November 1, 2025. He succeeds Michael F. Brigham, who will remain on the Board and serve as a Special Advisor. The company is also enhancing its leadership team with Timothy C. Fiori as CFO. A conference call is scheduled for November 14, 2025, to discuss financial results.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
ImmuCell Corporation announced preliminary, unaudited sales results for Q3 2025, indicating a decline in sales compared to previous quarters. This drop aligns with prior warnings about potential softening due to inventory re-stocking. The company remains committed to rebuilding market share and is working on developing a new treatment for mastitis in dairy cows.
Read more →ICCCImmuCell Announces Selection of its Next President and CEO
ImmuCell Corporation has appointed Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Te Boekhorst, who has a strong background in animal health and leadership roles at IDEXX Laboratories, is expected to drive growth for the company's products, First Defense® and Re-Tain®. Current CEO Michael F. Brigham will assist in the transition.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025
ImmuCell Corporation announced its unaudited financial results for the quarter ended June 30, 2025. The company reported an 18% increase in product sales to about $6.4 million, while also achieving a net income of approximately $502,000, a significant recovery from previous losses. Gross margins improved to 44%, suggesting enhanced profitability. Management noted inventory levels were restored to meet upcoming customer demand as they prepare for peak sales seasons in late 2025 and early 2026.
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended
ImmuCell Corporation announced its unaudited financial results for the quarter ended June 30, 2025, showcasing a positive turnaround with a net income of approximately $502,000. The company improved its gross margin to 44% during this period and has successfully eliminated its backlog of orders. Management indicates that they are building inventory in anticipation of increased demand moving into the peak selling season. However, the company has also noted potential risks regarding market adoption of their product, Re-Tain, which is currently undergoing evaluation.
Read more →ICCCImmuCell Announces Bank Debt Refinancing
ImmuCell Corporation has successfully refinanced a portion of its bank debt, securing a new loan of $2,327,119 from Maine Community Bank at a lower interest rate of 6.5%. This refinancing pays off previous loans with higher interest rates, enhancing the company's financial position. The company plans to discuss its financial results in an upcoming conference call.
Read more →ICCCImmuCell ImmuCell Announces Bank Debt Refinancing For Immediate Release
ImmuCell Corporation has announced the successful refinancing of a portion of its bank debt, securing a loan of approximately $2.3 million from Maine Community Bank at a lower interest rate of 6.5%. This refinancing allows ImmuCell to pay off previous loans with higher interest rates. The funds from this new loan will support the company's operations while improving its financial flexibility. The company plans to detail its financial results for the second quarter of 2025 in an upcoming conference call.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
ImmuCell Corporation, an animal health company, is scheduled to announce its unaudited financial results for the quarter ending June 30, 2025, on August 14, 2025. Following the announcement, a conference call will be held on August 15, 2025, to discuss the results, which are expected to align with preliminary sales previously disclosed. The company continues to focus on developing innovative products to enhance cattle health, including First Defense and the new Re-Tain product. Stakeholders can also access an updated corporate presentation on the company's website after the financial results are announced.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
ImmuCell Corporation reported preliminary, unaudited sales results for Q2 2025, revealing an 18% increase in sales compared to the same quarter in 2024. The Company has diminished its order backlog to under $100,000 and is looking to expand its production capacity further. Despite these positive trends, challenges still remain, including the delayed investment returns and regulatory hurdles for its products. Upcoming initiatives, such as the use of Re-Tain®, are set to test market acceptance, although they are not expected to significantly impact revenue.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 For Immediate Release
ImmuCell Corporation announced its preliminary unaudited sales results for Q2 2025, reporting an 18% increase in sales compared to the same quarter in 2024. The company has managed to reduce its order backlog to under $100,000 following increased production output. Additionally, ImmuCell is evaluating further investments to increase production capacity. While the introduction of Re-Tain is a promising initiative, it is not expected to generate substantial revenue in the short term.
Read more →ICCC▼ -10.8%on this news
ImmuCell Embarks on CEO Succession Planning Process
ImmuCell Corporation has initiated a search for a new President and CEO as Michael F. Brigham plans to retire by early 2026. Brigham, who has led the company since 2000, will assist in the transition and remains committed to his role until a suitable candidate is found. The Board aims to select a new leader by year-end.
Read more →ICCC▼ -10.8%on this newsshared move
ImmuCell ImmuCell Embarks on CEO Succession Planning Process For Immediate Release
ImmuCell Corporation has announced the commencement of a CEO succession planning process as Michael F. Brigham, the current President and CEO, plans to retire by early 2026. Brigham has been with the company since 1989 and has served as CEO since 2000. The company is actively seeking a successor and hopes to finalize the selection of a new leader by year-end, with Brigham remaining available to assist during the transition period. This move reflects the company's commitment to leadership continuity amid its growth in the animal health sector.
Read more →ICCCImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
ImmuCell Corporation will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025. Stockholders can participate via a telephone conference call or a live audio webcast. The company encourages stockholders to vote in advance and provides details for participation and proxy submission.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
ImmuCell Corporation reported its unaudited financial results for the first quarter of 2025, highlighting a record high in product sales at $8.1 million, which represents an 11% increase from the previous year. The company also achieved a net income of $1.4 million, marking a significant turnaround from a net loss the prior year. Improvements in gross margin were noted, rising to 42% compared to the last quarter of 2024. However, challenges remain, particularly concerning backlogs and the resolution of inspection issues with their contract manufacturer.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
ImmuCell Corporation (Nasdaq: ICCC) will announce its unaudited financial results for the quarter ending March 31, 2025, on May 14, 2025. A conference call is scheduled for May 15, 2025, to discuss these results. The company intends to file its Quarterly Report on Form 10-Q and anticipates no changes to previously disclosed preliminary sales results. This report will provide insights into the company's ongoing development of animal health products, including new treatments and vaccines for cattle.
Read more →ICCC▼ -10.6%on this news
ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 For Immediate Release
ImmuCell Corporation (Nasdaq: ICCC) announced preliminary unaudited sales results for Q1 2025, reporting record sales of $8.1 million, an increase of 11% from the same period last year. The company also noted that total sales for the twelve-month period reached $27.3 million, reflecting a substantial 28% growth. Despite these positive trends, the backlog of orders remains a challenge, and concerns about future production capacity due to prior contamination events persist. The upcoming launch of the Re-Tain product, aimed at treating subclinical mastitis, is in progress but is not expected to significantly impact revenues initially.
Read more →ICCC▼ -10.6%on this news
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
ImmuCell Corporation reported its preliminary unaudited sales results for Q1 of 2025, revealing a record quarterly sales figure of $8.1 million, an 11% increase compared to Q1 of 2024. The company also decreased its backlog of orders from $4.4 million to $4.0 million, signaling enhanced production efficiency. Additionally, both the six-month and twelve-month sales metrics set new records, showing significant growth year-over-year. The announcement comes as ImmuCell continues to invest in increasing its production capacity and preparing for the launch of its new product, Re-Tain®.
Read more →ICCCImmuCell Hires Chief Financial Officer
ImmuCell Corporation has announced the hiring of Timothy C. Fiori as its Chief Financial Officer. Fiori, who comes with 24 years of experience from IDEXX Laboratories, expresses enthusiasm about contributing to ImmuCell's growth. The company's leadership believes his expertise will enhance financial operations and drive the company forward. ImmuCell specializes in developing products aimed at improving the health and productivity of cattle.
Read more →ICCCImmuCell ImmuCell Hires Chief Financial Officer For Immediate Release
ImmuCell Corporation has appointed Timothy C. Fiori as its new Chief Financial Officer. Fiori, who has 24 years of experience from IDEXX Laboratories, looks forward to joining ImmuCell during a crucial phase of its development. Both Fiori and ImmuCell's President, Michael F. Brigham, emphasize the importance of his leadership in enhancing the company's growth strategies and operational efficiencies.
Read more →ICCC▲ +8.4%on this newsshared move
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain
ImmuCell Corporation has announced the initiation of Investigational Product use of Re-Tain, a product aimed at treating subclinical mastitis in dairy cows. This controlled launch will allow the company to test market acceptance and collect performance data while awaiting final NADA approval. However, the expected financial impact from this initiative is likely to be minimal, and uncertainties persist regarding the pending regulatory processes. ImmuCell's ongoing development efforts continue to focus on improving cattle health and productivity.
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended
ImmuCell Corporation announced its unaudited financial results for the quarter and year ended December 31, 2024, showcasing a significant increase in product sales and an improvement in gross margins. The company reported a positive EBITDA, contrasting with negative results from the previous year, while also noting the absence of any contamination events since April 2024. However, challenges remain regarding FDA approval for its product Re-Tain, with ongoing discussions for expedited review. The company is focusing on enhancing its production yields and gross margins as part of their recovery strategy.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
ImmuCell Corporation reported strong financial results for the fourth quarter and full year ended December 31, 2024. The company achieved a 52% increase in product sales, reaching approximately $7.8 million for the quarter and $26.5 million for the year. Improvements in gross margins and a transition to positive EBITDA were noted, reflecting recovery from previous contamination issues. The company also highlighted ongoing efforts to gain FDA approval for Re-Tain® and reported an increase in cash and stockholders' equity.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
ImmuCell Corporation is set to announce its unaudited financial results for the quarter and year ended December 31, 2024, on February 25, 2025. A conference call will follow on February 26, providing stakeholders with insights into the company's performance. The company expects no changes to previously reported preliminary sales results. Additionally, an updated corporate presentation will be available for investors shortly after the financial announcement.
Read more →ICCCImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses For Immediate Release
ImmuCell Corporation announced the settlement of an insurance claim related to contamination events that occurred between late 2022 and April 2024. The settlement amounts to $426,587, which complements a prior payment of $250,000 recognized in Q3 2023. This resolution is expected to alleviate some financial strain on the company. Additionally, ImmuCell continues to advance its product lines, including First Defense and Re-Tain, aimed at improving cattle health.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024 For Immediate Release
ImmuCell Corporation has announced its preliminary, unaudited sales results for the fourth quarter and full year 2024, reporting a significant increase in sales compared to the previous year. The company’s total sales reached $26.5 million in 2024, marking a 52% increase from 2023. They also noted an annualized production output of 103% of their estimated capacity, helping to reduce the backlog of orders. Additionally, ImmuCell is actively working towards FDA approval for its product Re-Tain while maintaining strong demand from distributors.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
ImmuCell Corporation has announced its preliminary, unaudited sales results for Q4 and the full year 2024, highlighting a significant 52% increase in sales compared to the previous year. The total sales for Q4 were reported at $7.8 million, up from $5.1 million in 2023, contributing to an annual total of $26.5 million compared to $17.5 million the prior year. Additionally, the company has successfully reduced its backlog of orders from $9.4 million to approximately $4.4 million, citing strong distributor demand. ImmuCell is also advancing its FDA approval process for Re-Tain®, targeting expedited reviews for its upcoming product.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
ImmuCell Corporation has announced its unaudited financial results for the quarter ended September 30, 2024, revealing an 11% increase in product sales compared to the same quarter in the previous year. The company has improved its cash position significantly while working towards regulatory approval for its novel product, Re-Tain®. Despite these positive developments, ImmuCell also reported a net loss and acknowledged potential risks linked to stockholder dilution and past contamination issues. Management remains optimistic about future growth as it focuses on stabilizing production systems.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
ImmuCell Corporation will announce its unaudited financial results for the quarter ending September 30, 2024, on November 13, 2024. Following the announcement, a conference call will take place on November 14, 2024, to discuss the results. The company expects no changes to previously disclosed preliminary sales figures. ImmuCell also intends to provide an updated corporate presentation to investors available on its website.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024 For Immediate Release
ImmuCell Corporation has reported preliminary, unaudited total sales results for the third quarter of 2024, revealing a significant increase in product sales compared to previous periods. For Q3 2024, sales reached $6.0 million, up 11% from $5.4 million in Q3 2023. Year-to-date results also show substantial growth, with nine-month sales up 51% to $18.7 million. The company also indicated a backlog of orders totaling approximately $7.3 million, attributed to strong demand. Additionally, ImmuCell continues to pursue FDA approval for its Re-Tain treatment and plans to provide further updates in the future.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
ImmuCell Corporation announced its preliminary unaudited sales results for Q3 2024, reporting an 11% increase over the same quarter last year, with total sales reaching $6.0 million. Year-to-date, sales have surged by 51% to $18.7 million. The company cited a backlog of approximately $7.3 million, driven by strong demand ahead of the calving season. Although the company continues to seek FDA approval for its Re-Tain® product, uncertainties regarding regulatory processes remain a concern.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
ImmuCell Corporation (ICCC) announced its unaudited financial results for Q2 2024, showing a significant 55% increase in product sales compared to the previous year. The company is still recovering from prior production contamination events but has ambitious goals for production capacity, aiming for $12 million in sales every six months. However, ImmuCell also reported a net loss of $1.5 million for the quarter, highlighting persistent challenges in profitability despite improved sales figures.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
ImmuCell Corporation (Nasdaq: ICCC) is set to announce its unaudited financial results for the quarter ended June 30, 2024, after market close on August 13, 2024. A conference call will follow on August 14, 2024, where the results will be reviewed. The company expects no changes to its preliminary sales results shared on July 9, 2024, and they will file their Quarterly Report on Form 10-Q accordingly. ImmuCell continues to focus on developing practical health products for dairy and beef cattle.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
ImmuCell Corporation reported preliminary, unaudited sales results for the second quarter of 2024, achieving $5.47 million, a 55% increase from the same period in 2023. The company's year-to-date sales reached $12.73 million, up 82% compared to the prior year. They plan to increase production capacity significantly while addressing FDA approval for their product Re-Tain®, expecting an update post-inspection. The company will host a conference call on August 14, 2024, to discuss these results further.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 For Immediate Release
ImmuCell Corporation has announced its preliminary, unaudited sales results for the second quarter of 2024, highlighting a 55% increase in revenue compared to the same quarter in 2023. Total sales reached $5.47 million, with the company aiming to enhance production capacity significantly in the second half of the year. The current backlog of orders stands at approximately $8.93 million, showcasing robust demand for their products. Additionally, ImmuCell continues to work towards gaining FDA approval for its product, Re-Tain, while maintaining transparency with its financial performance updates.
Read more →ICCC▲ +5%on this news
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain
ImmuCell Corporation provided an update on its regulatory status regarding Re-Tain, a product for dairy cattle. The company received a Technical Section Incomplete Letter from the FDA for its Chemistry, Manufacturing, and Controls section. In response, ImmuCell has prepared a fourth submission but cannot proceed until all inspectional observations are cleared. The FDA has indicated that ImmuCell's inspectional status is acceptable, and the company aims for a quicker review process for the upcoming submissions.
Read more →ICCC▲ +5%on this news
ImmuCell ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain For Immediate Release
ImmuCell Corporation has provided an update on its regulatory status regarding the product development initiative for Re-Tain. Following an Incomplete Letter from the FDA concerning its Chemistry, Manufacturing, and Controls (CMC) submission, the company is preparing a fourth submission to address non-complex comments from the FDA. The FDA has confirmed that ImmuCell's inspectional status is acceptable, allowing the company to proceed once the outstanding observations are cleared. If successful, ImmuCell anticipates submitting a combined filing that could lead to a controlled launch of Re-Tain between mid-2025 and early 2026.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
ImmuCell Corporation has reported impressive financial results for Q1 2024, with total sales reaching $7.3 million, marking a 111% increase year-over-year. Following a previous slowdown due to contamination issues, the company has successfully ramped up production capacity to nearly its estimated potential. However, a net loss of $438,000 was noted, underscoring ongoing financial challenges amidst significant sales growth. Additionally, the FDA has issued an Incomplete Letter regarding the company’s Re-Tain® product, necessitating further submissions.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
ImmuCell Corporation plans to announce its unaudited financial results for the quarter ending March 31, 2024, on May 14, 2024, after market close. The company has rescheduled the announcement from May 10, 2024. Following the release, a conference call is set for May 15, 2024, at 9:00 AM ET to review the results. ImmuCell expects no changes to its previously disclosed preliminary sales results and will also file its Quarterly Report on Form 10-Q on the same day as the results announcement.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 For Immediate Release
ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited sales results for Q1 2024, achieving a record high of $7.3 million, a 111% increase compared to the same period in 2023. The twelve-month total sales reached $21.3 million, up 33% from the previous year. The backlog of orders slightly decreased to approximately $9.1 million but remains significantly higher than past figures. ImmuCell is also continuing its efforts to gain FDA approval for its product, Re-Tain, with an expected update by May 2024.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
ImmuCell Corporation (Nasdaq: ICCC) has announced its preliminary, unaudited sales results for Q1 2024, reporting total sales of $7.3 million, a record high for the company. This figure represents a significant increase of 111% compared to Q1 2023 and a 42% increase from the previous quarter. The company also noted a backlog of orders amounting to approximately $9.1 million. Additionally, ImmuCell is working towards FDA approval for its product Re-Tain, with expectations of a response by May 2024.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended
ImmuCell Corporation announced its unaudited financial results for the quarter and year ended December 31, 2023. The company reported a 30% increase in sales for the fourth quarter compared to the same period in 2022, although total sales for the year decreased by 6%. Production was impacted earlier in the year due to contamination issues, but improved in the latter months. ImmuCell is also working towards FDA approval for its novel antibiotic alternative, Re-Tain, with expectations of a response by May 2024.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
ImmuCell Corporation announced that it will report its unaudited financial results for the quarter and year ended December 31, 2023, on February 27, 2024, after the market closes. This announcement has been delayed by six days from its initially scheduled date. A conference call to discuss these results will take place on February 28, 2024. The company expects no change to the preliminary sales results disclosed earlier.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 For Immediate Release
ImmuCell Corporation announced preliminary, unaudited sales results for Q4 2023, revealing a 30% increase in sales compared to the same period in the previous year. For the full year 2023, total sales decreased by 6%, primarily due to production issues stemming from contamination events. Despite these challenges, the company expressed optimism about increasing production capacity in 2024 and reducing its backlog of orders, which now stands at approximately $9.4 million. The company is also awaiting FDA approval for its product, Re-Tain, expected by May 2024.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023
ImmuCell Corporation reported its unaudited financial results for the quarter ending September 30, 2023, noting a 13% increase in product sales compared to the same quarter last year. Despite this growth, the company reported a net loss of $940,000, worsening from the prior year. The decrease in gross margin was attributed to contamination events that affected production. Going forward, ImmuCell is optimistic about its plans to enhance production capacity and introduce innovative products to the market, such as Re-Tain® pending FDA approval.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
ImmuCell Corporation plans to announce its unaudited financial results for the quarter ending September 30, 2023, on November 13, 2023. The company is not expecting any changes to its preliminary sales results disclosed in early October. A conference call is scheduled for the following day to review these results, aiming to provide further details to investors. ImmuCell continues to develop innovative health products for dairy and beef cattle, including 'First Defense' and a new treatment for mastitis.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023 For Immediate Release
ImmuCell Corporation announced its preliminary sales results for Q3 2023, marking a notable increase in sales compared to the previous year. While the company's total sales for the three-month period ended September 30, 2023, reached $5.40 million, they reported declines in total sales for the nine-month and twelve-month comparisons to 2022. The increase in production output is attributed to recent investments, although challenges remain due to a contamination incident and a growing backlog of orders. The company continues its efforts toward obtaining FDA approval for its product Re-Tain and will discuss its financial results in an upcoming conference call.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
ImmuCell Corporation announced its preliminary, unaudited sales results for Q3 2023, reporting a 13% increase to $5.40 million compared to $4.80 million in the same quarter of 2022. However, the company experienced declines in sales for the nine-month and trailing twelve-month periods compared to 2022. Despite facing challenges like a contamination event and production delays, ImmuCell is working to increase production output to meet demand, evidenced by a growing backlog of orders now totaling $8.9 million. The company is also pursuing FDA approval for its novel treatment, Re-Tain, with a recent submission under review.
Read more →ICCCImmuCell Announces Submission of CMC Technical Section to the FDA
ImmuCell Corporation (NASDAQ: ICCC) announced the submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section for its product Re-Tain® to the FDA. This submission, which took place on August 18, 2023, follows the company's prior announcement of a planned timeline. The FDA review process is anticipated to take six months, during which the company expressed optimism about future opportunities related to this product. Re-Tain® is designed to treat subclinical mastitis in dairy cows without the need for milk discard, positioning itself as an alternative to traditional antibiotics.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
ImmuCell Corporation announced its unaudited financial results for the quarter ended June 30, 2023, revealing a significant decline in product sales and an increase in net loss compared to the previous year. The company cited a production contamination event as a key factor affecting its performance but noted that quality control measures have improved, enabling a path back to full production. Additionally, they are continuing efforts to advance their product Re-Tain®, aimed at revolutionizing subclinical mastitis treatment in dairy cattle while preparing for a critical FDA submission.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
ImmuCell Corporation, a company focused on animal health products, is set to announce its unaudited financial results for the quarter ended June 30, 2023, on August 10, 2023. A conference call will be held the following morning to discuss these financial results. The company does not anticipate any changes to its previously disclosed preliminary sales results. Additionally, ImmuCell continues to innovate with its product offerings, including First Defense® and the upcoming Re-Tain® treatment for cattle.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023
ImmuCell Corporation announced preliminary, unaudited sales results for Q2 2023, reporting a decline in total sales compared to the same quarter last year. The company experienced a 9% decrease in Q2 sales, attributed to a production slowdown related to contamination issues earlier in the year. However, production output improved in June, indicating potential recovery. A significant backlog of orders reflects growing demand. Additionally, ImmuCell is continuing efforts to achieve FDA approval for its product Re-Tain, with a submission expected by the end of July 2023.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023 For Immediate Release
ImmuCell Corporation reported preliminary sales results for Q2 2023, showing a decline in total sales compared to the previous year. Total sales reached $3.53 million, marking a 9% decrease from Q2 2022. This downturn was attributed to a production slowdown enacted in early 2023 to address contamination issues. Despite the drop, the company noted a significant increase in order backlog and modest recovery in production output towards the end of the quarter, indicating potential improvement in the latter half of 2023.
Read more →ICCC▼ -10.4%on this news
ImmuCell Announces Change in Timing of Anticipated FDA Submission
ImmuCell Corporation has announced a one-month delay in its anticipated FDA submission for its product Re-Tain, which targets subclinical mastitis in dairy cows. While the CMC Technical Section is ready for submission, the company is opting for additional time to prepare for the related pre-approval re-inspection. This announcement reflects the company's focus on ensuring thoroughness in their regulatory development process. ImmuCell is known for developing products that enhance the health and productivity of dairy and beef cattle.
Read more →ICCCImmuCell Appoints Bryan K. Gathagan to Board of Directors
ImmuCell Corporation announced the appointment of Bryan K. Gathagan to its Board of Directors, highlighting his 25 years of experience in the animal health sector and financial acumen. Gathagan, who is the owner of broad Thinking, LLC and a founding member of Animalytix LLC, will contribute valuable insights to the company's operations. The leadership at ImmuCell is enthusiastic about his addition and the potential impact on the company's growth strategies. Gathagan expressed excitement about joining the board and supporting the leadership team.
Read more →ICCCImmuCell ImmuCell Appoints Bryan K. Gathagan to Board of Directors For Immediate Release
ImmuCell Corporation has announced the appointment of Bryan K. Gathagan to its Board of Directors. Gathagan, who has extensive experience in the animal health industry, is also a managing member of a management consulting firm and previously held executive positions at Animalytix LLC and Intervet, Inc. His background in finance and technology is anticipated to bolster ImmuCell's operations and strategic planning. Both Gathagan and ImmuCell's President expressed enthusiasm for the collaboration.
Read more →ICCCImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility
ImmuCell Corporation announced the approval of a $3 million debt facility, which includes a $2 million loan from Gorham Savings Bank and a $1 million direct loan from the Finance Authority of Maine. This funding is expected to improve the company's cash position following a loss in the first quarter and help address an order backlog of approximately $8.2 million. The company has reported significant improvements in its quality control tests after overcoming a production contamination issue and aims to resume full production by the second half of 2023.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023
ImmuCell Corporation announced its unaudited financial results for the quarter ending March 31, 2023, reporting a significant decrease in product sales and a net operating loss of $2.3 million. The company faced challenges due to a production contamination event, resulting in a backlog and reduced output. Management is implementing operational improvements and aims to increase production capacity over time. Despite the setbacks, the company is working on regulatory submissions and hopes to stabilize supply as it moves forward.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
ImmuCell Corporation is preparing to report its unaudited financial results for the quarter that ended on March 31, 2023. The report is expected to be released after market close on May 11, 2023, followed by a conference call on May 12 to discuss the results. The company anticipates no changes to its preliminary sales results disclosed earlier. Additionally, ImmuCell continues its efforts in developing innovative products to enhance animal health.
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023 For Immediate Release
ImmuCell Corporation announced preliminary, unaudited sales results for the first quarter of 2023, reporting sales of $3.45 million, which is below prior year results but exceeded their previous projections. The decrease in sales is attributed to a production slowdown due to contamination events affecting manufacturing. However, the company indicated improvements in their quality control measures and an increase in order backlog, suggesting potential recovery. They are also working towards FDA approval for their product Re-Tain, with a submission expected by the end of April 2023.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023
ImmuCell Corporation (Nasdaq: ICCC) announced its preliminary, unaudited sales results for Q1 2023, reporting sales of $3.45 million, a 43% decrease from the same period in 2022. The decline is attributed to a production slowdown caused by contamination events in the previous months. However, the company noted that sales slightly exceeded previous projections and the order backlog has significantly increased. Improved quality control measures are in place as the company prepares to ramp up production heading into Q2.
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for the Year Ended
ImmuCell Corporation has announced its unaudited financial results for the year ended December 31, 2022, revealing a significant increase in order backlogs primarily due to production slowdowns caused by contamination events. The company reported a net operating loss, and plans to defer further investments in production capacity expansion while addressing these quality control issues. Despite the challenges, ImmuCell is optimistic about the future demand for its First Defense product line and expects to implement corrective actions to mitigate contamination risks going forward.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022
ImmuCell Corporation announced its unaudited financial results for the year ending December 31, 2022, revealing a net loss and decreased gross margin largely attributed to product contamination issues. The company is currently facing a second contamination event that has slowed production and caused a significant backlog of orders. Despite these challenges, ImmuCell is working on expanding production capacity and preparing for regulatory submissions for its new products, which it believes are crucial for future growth.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
ImmuCell Corporation (Nasdaq: ICCC) plans to announce its unaudited financial results for the year ended December 31, 2022, after market closing on February 21, 2023. A conference call to review the results is scheduled for February 22, 2023, at 9:00 AM ET. The company also plans to file its Annual Report on Form 10-K around March 29, 2023, and is expected to update its corporate presentation for investors. ImmuCell continues to develop products that enhance the health and productivity of livestock.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022
ImmuCell Corporation announced preliminary, unaudited sales results for the year ended December 31, 2022, reporting a slight revenue decline of 3.5% compared to 2021. Despite this dip, a backlog of orders totaling approximately $2.5 million suggests a healthy demand for its products, particularly the First Defense® line. The company faced delays in production equipment implementation, which hampered its operational goals for the year. Moving forward, ImmuCell is focused on obtaining regulatory approval for its Re-Tain® product in the upcoming months.
Read more →ICCC▲ +6.2%on this news
ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended
Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022 Maine - January 9, 2023 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and pra
Read more →ICCC▼ -11.3%on this news
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
PORTLAND, Maine, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell to Announce Unaudited Financial Results for the Quarter Ended
ImmuCell to Announce Unaudited Financial Results the Quarter Ended September 30, 2022 Conference Call Scheduled for Tuesday, November 22, 2022 at 9:00 AM ET PORTLAND, Maine - November 10, 2022 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing ani
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022
PORTLAND, Maine, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022 For Immediate Release
ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022 PORTLAND, Maine - October 5, 2022 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-prov
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022
PORTLAND, Maine, Oct. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
PORTLAND, Maine, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCSECOND AMENDMENT OF LEASE This is a Second Amendment of Lease (this "Amendment") is dated as of this 15th day of August, 2022, by and between TVP, LLC, with a mailing address of P.O. Box 66749, Falmouth, Maine 04105 (her
SECOND AMENDMENT OF LEASE This is a Second Amendment of Lease (this "Amendment") is dated as of this 15th day of August, 2022, by and between TVP, LLC, with a mailing address of P.O. Box 66749, Falmouth, Maine 04105 (hereinafter the "Landlord"), and ImmuCell Corporation with a
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022
PORTLAND, Maine, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
PORTLAND, Maine, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain
PORTLAND, Maine, July 27, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain For Immediate Release
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain PORTLAND, Maine - July 27, 2022 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-pro
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
PORTLAND, Maine, July 07, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022 For Immediate Release
Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022 Maine - July 7, 2022 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical produc
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
PORTLAND, Maine, May 12, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCC▼ -8.1%on this newsshared move
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
PORTLAND, Maine, May 10, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022 For Immediate Release
Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022 PORTLAND, Maine - April 11, 2022 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven a
Read more →ICCCImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022
PORTLAND, Maine, April 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCALLONGE TO AND AMENDMENT OF TERM NOTE Loan No. 8160005131 This Allonge to and Amendment of Term Note (this "Allonge") refers to the loan evidenced by a Promissory Note (#8160005131) dated
ALLONGE TO AND AMENDMENT OF TERM NOTE This Allonge to and Amendment of Term Note (this "Allonge") refers to the loan evidenced by a Promissory Note (#8160005131) dated March 11, 2020 in the original amount of Five Million One Hundred Thousand and 00/100 Dollars ($5,100,000.00)
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
PORTLAND, Maine, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCINDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement ("Agreement") is made and effective as of
INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement ("Agreement") is made and effective as of February 11, 2022 between Joseph Crabb ("Consultant") and ImmuCell Corporation, a Delaware corporation Now, therefore, Consultant and Company agree as Resignation;
Read more →ICCC▲ +10.3%on this news
ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021
PORTLAND, Maine, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended
Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021 Maine - January 5, 2022 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2021
PORTLAND, Maine, Nov. 15, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended
ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000) PORTLAND, Maine - November 15, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health c
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Third Quarter Ended September 30, 2021
PORTLAND, Maine, Nov. 09, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021
PORTLAND, Maine, Oct. 06, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021 For Immediate Release
Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021 Maine - October 6, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practic
Read more →ICCC▼ -6.1%on this news
ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain
PORTLAND, Maine, Aug. 24, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCC▼ -6.1%on this news
ImmuCell ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain For Immediate Release
Required to Prepare Second Submission of Final Major Technical Section for Re-Tain Maine - August 24, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and prac
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2021
PORTLAND, Maine, Aug. 12, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended
Announces Unaudited Financial Results for Second Quarter Ended June 30, 2021 Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000) Maine - August 12, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Second Quarter Ended June 30, 2021
PORTLAND, Maine, Aug. 05, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021 For Immediate Release
ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021 PORTLAND, Maine - July 7, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically
Read more →ICCCImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021
PORTLAND, Maine, July 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCNOTE PURCHASE AGREEMENT This Note Purchase Agreement, ("Agreement"), is made as of
Note Purchase Agreement, ("Agreement"), is made as of June 30, 2021, by and between the Maine Technology Institute, a non-profit corporation organized under the laws of the State of Maine ("Holder"), and ImmuCell Corporation, a Corporation organized under the laws of the State
Read more →ICCCImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021
PORTLAND, Maine, May 13, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for the First Quarter Ended
ImmuCell Announces Unaudited Financial Results the First Quarter Ended March 31, 2021 PORTLAND, Maine - May 13, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-pro
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the First Quarter Ended March 31, 2021
PORTLAND, Maine, May 06, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Closes $4,250,000 Equity Financing
ImmuCell Closes $4,250,000 Equity Financing PORTLAND, Maine - April 14, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve t
Read more →ICCCImmuCell Closes $4,250,000 Equity Financing
PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021
PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021 For Immediate Release
ImmuCell Announces Preliminary, Unaudited Sales First Quarter of 2021 PORTLAND, Maine - April 7, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practic
Read more →ICCCImmuCell ImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended
ImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended December 31, 2020 PORTLAND, Maine - February 22, 2021 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops
Read more →ICCCImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended December 31, 2020
PORTLAND, Maine , Feb. 22, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020
PORTLAND, Maine, Feb. 16, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2020
PORTLAND, Maine, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Restructuring of its Bank Debt For Immediate Release
Announces Restructuring of its Bank Debt Maine - December 15, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health
Read more →ICCCImmuCell Announces Restructuring of its Bank Debt
PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2020
PORTLAND, Maine, Nov. 12, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Unaudited Financial Results for Third Quarter of 2020
PORTLAND, Maine, Nov. 05, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020
PORTLAND, Maine, Oct. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended
Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020 PORTLAND, Maine - October 6, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven an
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2020
PORTLAND, Maine, Aug. 12, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Unaudited Financial Results for Second Quarter of 2020
PORTLAND, Maine, Aug. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020
PORTLAND, Maine, July 07, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended
ImmuCell Announces Preliminary, Unaudited the Second Quarter Ended June 30, 2020 PORTLAND, Maine - July 7, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven a
Read more →ICCCImmuCell Receives $500,000 Loan from the Maine Technology Institute For Immediate Release
Receives $500,000 Loan from Maine Technology Institute Maine - June 16, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve
Read more →ICCCImmuCell Corporation to Present at Lytham Partners Virtual Investor Conference On Tuesday, May 20 th at 11:00 am ET Portland, Maine
Corporation to Present at Partners Virtual Investor Conference Tuesday, May 20th at 11:00 am ET Maine -- May 14, 2020 -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical products th
Read more →ICCCImmuCell ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders For Immediate Release
to Hold Virtual-Only Annual Meeting of Stockholders PORTLAND, Maine - May 14, 2020 - ImmuCell Corporation (Nasdaq: ICCC) (the "Company" or "ImmuCell"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that imp
Read more →ICCCImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2020
PORTLAND, Maine, May 13, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell to Announce Unaudited Financial Results for First Quarter of 2020
PORTLAND, Maine, May 07, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell Receives $938,000 in Support under the Paycheck Protection Program
PORTLAND, Maine, April 14, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Receives $938,000 in Support under the Paycheck Protection Program For Immediate Release
ImmuCell Receives $938,000 in Support under the Paycheck Protection Program PORTLAND, Maine - April 14, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and
Read more →ICCCImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020
PORTLAND, Maine, April 02, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended
Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020 PORTLAND, Maine - April 2, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifical
Read more →ICCCImmuCell ImmuCell Announces Refinancing of its Bank Debt For Immediate Release
Announces Refinancing of its Bank Debt Maine - March 11, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and p
Read more →ICCCImmuCell Announces Refinancing of its Bank Debt
PORTLAND, Maine, March 11, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended
Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019 PORTLAND, Maine - February 19, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops
Read more →ICCCImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019
PORTLAND, Maine, Feb. 19, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2019
PORTLAND, Maine, Feb. 18, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Preliminary Financial Results for the Year Ended December 31, 2019
PORTLAND, Maine, Feb. 13, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCAnnounces Preliminary, Unaudited Product Sales Results
Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019 PORTLAND, Maine - January 21, 2020 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientif
Read more →ICCCImmuCell Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019
PORTLAND, Maine, Jan. 21, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019 For Immediate Release
ImmuCell Announces Unaudited Financial Results Third Quarter of 2019 PORTLAND, Maine - November 11, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and prac
Read more →ICCCImmuCell Announces Unaudited Financial Results for Third Quarter of 2019
PORTLAND, Maine, Nov. 11, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Unaudited Financial Results for Third Quarter of 2019
PORTLAND, Maine, Nov. 05, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense Production Capacity For Immediate Release
Enters into Lease Agreement for a Facility to Expand First Defense Production Capacity Maine - September 17, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company") - a growing animal health company that develops, manufactures and markets scientifically-proven
Read more →ICCCImmuCell Enters into Lease Agreement for a Facility to Expand First Defense Production Capacity
PORTLAND, Maine, Sept. 17, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain For Immediate Release
ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain PORTLAND, Maine - September 11, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company") - a growing animal health company that develops, manufactures and mark
Read more →ICCCImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™
PORTLAND, Maine, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell Receives FDA Response To First CMC Submission for Re-Tain™
Second Submission Anticipated Around Q3 2020 PORTLAND, Maine, Aug. 29, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical product
Read more →ICCCImmuCell ImmuCell Receives FDA Response To First CMC Submission for Re-Tain Second Submission Anticipated Around Q3 2020 For Immediate Release
ImmuCell Receives FDA Response To First CMC Submission for Re-Tain Second Submission Anticipated Around PORTLAND, Maine - August 29, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company") - a growing animal health company that develops, manufactures and mar
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019 For Immediate Release
Announces Unaudited Financial Results for Maine - August 12, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company") - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health
Read more →ICCCImmuCell Announces Unaudited Financial Results for Second Quarter of 2019
PORTLAND, Maine, Aug. 12, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell to Announce Unaudited Financial Results for Second Quarter of 2019
PORTLAND, Maine, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces Unaudited Financial Results for First Quarter of 2019 For Immediate Release
ImmuCell Announces Unaudited Financial First Quarter of 2019 PORTLAND, Maine - May 13, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company") - a growing animal health company that develops, manufactures and markets scientifically-proven and practical produc
Read more →ICCCImmuCell Announces Unaudited Financial Results for First Quarter of 2019
PORTLAND, Maine, May 13, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Unaudited Financial Results for First Quarter of 2019
PORTLAND, Maine, May 07, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCAMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Amended and Restated Incentive Compensation Agreement, dated as of
AMENDED AND RESTATED INCENTIVE COMPENSATION This Amended and Restated Incentive Compensation Agreement, dated as of April 11, 2019, is by and between ImmuCell Corporation, a Delaware corporation (the "Company") and Bobbi Jo Brockmann (the "Executive"), and replaces and superse
Read more →ICCCImmuCell Corporation Announces Closing of $9 Million Public Offering of Common Stock
PORTLAND, Maine, March 29, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell Corporation Announces Pricing of $9.0 Million Public Offering of Common Stock
PORTLAND, Maine, March 27, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Corporation Announces Commencement of Public Offering of Common Stock For Immediate Release
ImmuCell Corporation Announces Commencement of Public Offering of Common Stock PORTLAND, Maine - March 26, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven a
Read more →ICCCImmuCell Corporation Announces Commencement of Public Offering of Common Stock
PORTLAND, Maine, March 26, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces Submission of Manufacturing Technical Section for its Purified Nisin Product For Immediate Release
Announces Submission of Manufacturing Technical Section for its Purified Nisin Product PORTLAND, Maine - February 28, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientificall
Read more →ICCCImmuCell Announces Submission of Manufacturing Technical Section for its Purified Nisin Product
PORTLAND, Maine, Feb. 28, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2018
PORTLAND, Maine, Feb. 13, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2018 For Immediate Release
Announces Preliminary Financial Results for Quarter and Full Year 2018 Maine - February 13, 2019 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company") - a growing animal health company that develops, manufactures and markets scientifically-proven and practical p
Read more →ICCCImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2018
PORTLAND, Maine, Feb. 06, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Announces USDA Approval of Dual-Force™ First Defense
PORTLAND, Maine, Dec. 11, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces USDA Approval of Dual-Force First Defense For Immediate Release PORTLAN D, Maine
ImmuCell Announces USDA Approval of Maine - December 11, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and p
Read more →ICCCImmuCell Announces Financial Results for Third Quarter of 2018
PORTLAND, Maine, Nov. 13, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Financial Results for Third Quarter of 2018 For Immediate Release
Financial Results for PORTLAND, Maine - November 13, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and produ
Read more →ICCCImmuCell to Participate at 9th Annual Craig-Hallum Alpha Select Conference
PORTLAND, Maine, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Financial Results for Third Quarter of 2018
Conference Call Scheduled for Wednesday, November 14, 2018 at 9:00 AM ET PORTLAND, Maine, Nov. 07, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-p
Read more →ICCCImmuCell Announces Issuance of Human Food Safety Technical Section Complete Letter for its Purified Nisin Product
PORTLAND, Maine, Sept. 25, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
Read more →ICCCImmuCell ImmuCell Announces Issuance of Human Food Safety Technical Section Complete Letter for its Purified Nisin Product For Immediate Release
ImmuCell Announces Issuance of Human Food Safety Technical Section Complete Letter for its Purified Nisin Product PORTLAND, Maine - September 25, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactu
Read more →ICCCImmuCell ImmuCell Announces Financial Results for Second Quarter of 2018 For Immediate Release
ImmuCell Announces Financial Results for Second Quarter of 2018 PORTLAND, Maine - August 13, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical p
Read more →ICCCImmuCell Announces Financial Results for Second Quarter of 2018
PORTLAND, Maine, Aug. 13, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell Hires Senior Director of Quality
PORTLAND, Maine, Aug. 07, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Financial Results for Second Quarter of 2018
PORTLAND, Maine, Aug. 07, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell ImmuCell Announces Sale of Certain Non-Core Assets For Immediate Release
Sale of Certain Non-Core Assets PORTLAND, Maine - July 25, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health an
Read more →ICCCImmuCell Announces Sale of Certain Non-Core Assets
PORTLAND, Maine, July 25, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell Announces Preliminary Sales Results for Second Quarter of 2018
PORTLAND, Maine, July 10, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Announces Preliminary Sales Results for Second Quarter of 2018 For Immediate Release
ImmuCell Announces Preliminary Sales Results Second Quarter of 2018 PORTLAND, Maine - July 10, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical
Read more →ICCCImmuCell to Join Russell Microcap Index
PORTLAND, Maine, June 25, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Announces Financial Results for First Quarter of 2018 For Immediate Release
ImmuCell Announces Financial Results for First Quarter of 2018 PORTLAND, Maine - May 14, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical produ
Read more →ICCCImmuCell Announces Financial Results for First Quarter of 2018
PORTLAND, Maine, May 14, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dai
Read more →ICCCImmuCell to Announce Financial Results for First Quarter of 2018
PORTLAND, Maine, May 07, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dai
Read more →ICCCImmuCell ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2017 For Immediate Release
ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2017 PORTLAND, Maine - February 8, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifical
Read more →ICCCImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2017
PORTLAND, Maine, Feb. 08, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of d
Read more →ICCCImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017
PORTLAND, Maine, Feb. 05, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Appoints Two New Members to its Board of Directors For Immediate Release
ImmuCell Appoints Two New Members to its Board of Directors PORTLAND, Maine - January 30, 2018 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical prod
Read more →ICCCImmuCell Appoints Two New Members to its Board of Directors
PORTLAND, Maine, Jan. 30, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Corporation Announces Closing of $3 Million Public Offering of Common Stock FOR IMMEDIATE RELEASE
ImmuCell Corporation Announces Closing of $3 Million Public Offering of Common Stock FOR IMMEDIATE RELEASE: PORTLAND, Maine - December 21, 2017 - ImmuCell Corporation ("ImmuCell" or the "Company") (Nasdaq: ICCC), a growing animal health company that develops, manufactures an
Read more →ICCCImmuCell Corporation Announces Closing of $3 Million Public Offering of Common Stock
PORTLAND, Maine, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (“ImmuCell” or the “Company”) (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell ImmuCell Corporation Announces Pricing of $3 Million Public Offering of Common Shares
Corporation Announces Pricing of $3 Million Public Offering of Common Shares PORTLAND, Maine - December 19, 2017 - ImmuCell Corporation ("ImmuCell" or the "Company") (Nasdaq: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven a
Read more →ICCCImmuCell Corporation Announces Pricing of $3 Million Public Offering of Common Shares
PORTLAND, Maine, Dec. 19, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (“ImmuCell” or the “Company”) (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da
Read more →ICCCImmuCell Announces Financial Results for Third Quarter of 2017
PORTLAND, Maine, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve the health and productivity of dairy and beef cattle, today announced unaudit
Read more →ICCCImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections
PORTLAND, Maine, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve the health and productivity of dairy and beef cattle, today announced that th
Read more →ICCCImmuCell ImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections
Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections Maine - November 13, 2017 - ImmuCell Corporation (Nasdaq: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve the health and produc
Read more →ICCCImmuCell ImmuCell Announces Financial Results for Third Quarter of 2017
Announces Financial Results for Third Quarter of 2017 Maine - November 13, 2017 - ImmuCell Corporation (Nasdaq: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve the health and productivity of dairy and be
Read more →ICCCImmuCell Announces Completion of Construction of Nisin Production Facility
PORTLAND, Maine, Nov. 07, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve the health and productivity of dairy and beef cattle, today announced complet
Read more →ICCCImmuCell to Announce Financial Results for Third Quarter of 2017
PORTLAND, Maine, Nov. 02, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve the health and productivity of dairy and beef cattle, will report financial r
Read more →ICCCImmuCell Announces Expansion of Sales and Marketing Team
PORTLAND, Maine, Sept. 13, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve health and productivity in the dairy and beef industries, today announced th
Read more →ICCCImmuCell September 1. 2017 Michael Brigham President ImmuCell Corporation 56 Evergreen Dr. Portland, ME 04103 Dear Michael, Please consider this my resignation from our board of directors, effective immediately. I look f
consider this my resignation from our board of directors, effective immediately. I look forward to the opportunity to rejoin the board at a time that makes sense for our business and when our inside/outside director seats meet the required ratio. 56 Evergreen Drive - Portland,
Read more →ICCCImmuCell Announces Financial Results for Second Quarter of 2017
PORTLAND, Maine, Aug. 14, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve health and productivity in the dairy and beef industries, today announced una
Read more →ICCCAnnounces Financial Results for Second Quarter of 2017
Announces Financial Results for Second Quarter of 2017 Maine - August 14, 2017 - ImmuCell Corporation (NasdaqCM: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve health and productivity in the dairy and b
Read more →ICCCMEMO To: Board of Directors, ImmuCell From: Linda Rhodes, VMD, PhD Date
Board of Directors, ImmuCell Linda Rhodes, VMD, PhD Resignation from the ImmuCell Board of Directors was elected to the Board of Directors of Zoetis effective August 3, 2017. Although legally there is no conflict of interest in serving on both the ImmuCell and Zoetis Boards,
Read more →ICCCImmuCell to Announce Financial Results for Second Quarter of 2017
PORTLAND, Maine, Aug. 07, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve animal health and productivity in the dairy and beef industries, will report
Read more →ICCCImmuCell Closes $1,000,000 Equity Investment
PORTLAND, Maine, July 27, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve health and productivity in the dairy and beef industries, today announced tha
Read more →ICCCImmuCell ImmuCell Closes $1,000,000 Equity Investment
Closes $1,000,000 Equity Investment Maine - July 27, 2017 - ImmuCell Corporation (NasdaqCM: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve health and productivity in the dairy and beef industries, toda
Read more →ICCCImmuCell Unveils New Website
PORTLAND, Maine, July 17, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve health and productivity in the dairy and beef industries, today introduced a
Read more →ICCCImmuCell Clarifies Number of Authorized Common Shares
PORTLAND, Maine, July 13, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven products that improve health and productivity in the dairy and beef industries, today announced tha
Read more →ICCCImmuCell FOR IMMEDIATE RELEASE: ImmuCell Announces Financial Results for First Quarter of 2017
FOR IMMEDIATE RELEASE: ImmuCell Announces Financial Results for First Quarter of 2017 PORTLAND, Maine - May 11, 2017 - ImmuCell Corporation (NasdaqCM: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and produc
Read more →ICCCBobbi Jo Brockmann is appointed to Board of Directors of ImmuCell Corporation For Immediate Release
Bobbi Jo Brockmann is appointed to Board of Directors of ImmuCell Corporation PORTLAND, Maine - March 8, 2017 - ImmuCell Corporation (NasdaqCM: ICCC), today announced that Ms. Bobbi Jo Brockmann was appointed to its Board of Directors effective March 7, 2017. Ms. Brockmann will
Read more →ICCCImmuCell Secures $2 Million in Debt Financing
PORTLAND, ME--(Marketwired - March 02, 2017) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced that it has secured $2
Read more →ICCCImmuCell Announces Preliminary 2016 Financial Results PORTLAND, ME -- (Marketwired
ImmuCell Announces Preliminary 2016 Financial Results PORTLAND, ME -- (Marketwired - February 09, 2017) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy
Read more →ICCCImmuCell to Announce Preliminary 2016 Financial Results
PORTLAND, ME--(Marketwired - February 06, 2017) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report unaudited 2016 f
Read more →ICCCImmuCell to Present at the 7th Annual Craig-Hallum Alpha Select Conference
PORTLAND, ME--(Marketwired - November 10, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced that Michael F. Bri
Read more →ICCCImmuCell Announces Third Quarter 2016 Financial Results
PORTLAND, ME--(Marketwired - November 10, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results f
Read more →ICCCImmuCell to Announce Third Quarter 2016 Financial Results Conference Call Scheduled for Thursday, November 10, 2016 at 4:30 PM ET
PORTLAND, ME--(Marketwired - November 03, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report third quarter 20
Read more →ICCCImmuCell Corporation Announces Closing of $3.5 Million Private Placement of Common Stock
PORTLAND, ME--(Marketwired - October 21, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the closing of a pre
Read more →ICCCImmuCell NOT FOR RELEASE: ImmuCell Corporation Announces Closing of $3.5 Million Private Placement of Common Stock Contact: Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum
ImmuCell Corporation Announces Closing of $3.5 Million Private Placement of Common Stock Contact: Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com POR
Read more →ICCCImmuCell Announces Preliminary Third Quarter 2016 Financial Results PORTLAND, ME -- (Marketwired
ImmuCell Announces Preliminary Third Quarter 2016 Financial Results PORTLAND, ME -- (Marketwired - October 18, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity
Read more →ICCCImmuCell Announces Preliminary Third Quarter 2016 Financial Results
PORTLAND, ME--(Marketwired - October 18, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced preliminary financia
Read more →ICCCImmuCell to Raise $3.5 Million in Private Placement
PORTLAND, ME--(Marketwired - October 18, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced it has entered into
Read more →ICCCImmuCell to Raise $3.5 Million in Private Placement PORTLAND, ME -- (Marketwired
ImmuCell to Raise $3.5 Million in Private Placement PORTLAND, ME -- (Marketwired - October 18, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy an
Read more →ICCCImmuCell Breaks Ground for Mast Out(R) Facility PORTLAND, ME -- (Marketwired
ImmuCell Breaks Ground for Mast Out(R) Facility PORTLAND, ME -- (Marketwired - October 11, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and be
Read more →ICCCImmuCell Breaks Ground for Mast Out(R) Facility
PORTLAND, ME--(Marketwired - October 11, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced that it has broken g
Read more →ICCCImmuCell Announces Second Quarter 2016 Financial Results
PORTLAND, ME--(Marketwired - August 11, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results for
Read more →ICCCImmuCell to Announce Second Quarter 2016 Financial Results
PORTLAND, ME--(Marketwired - August 03, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report second quarter 201
Read more →ICCCImmuCell Announces First Quarter 2016 Financial Results PORTLAND, ME -- (Marketwired
ImmuCell Announces First Quarter 2016 Financial Results PORTLAND, ME -- (Marketwired - May 11, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy an
Read more →ICCCImmuCell Announces First Quarter 2016 Financial Results
PORTLAND, ME--(Marketwired - May 11, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results for
Read more →ICCCImmuCell to Announce First Quarter 2016 Financial Results
PORTLAND, ME--(Marketwired - May 04, 2016) - ImmuCell Corporation , a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report first quarter 2016 financial resu
Read more →ICCCImmuCell Appoints Elizabeth Williams Vice President of Manufacturing Operations
PORTLAND, ME--(Marketwired - April 04, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the hiring of Ms. El
Read more →ICCCSecond Amended and Restated Loan Agreement This Agreement is entered into this 28th day of March, 2016 by, between and among ImmuCell Corporation (the " Borrower ") and TD Bank, N.A . (together with its successors and as
Amended and Restated Loan Agreement Agreement is entered into this 28th day of March, 2016 by, between and among ImmuCell Corporation (the "Borrower") and TD Bank, N.A. (together with its successors and assigns, the "Lender"), for itself and as agent for any Affiliate Counterp
Read more →ICCCImmuCell Announces Full Year 2015 Financial Results
PORTLAND, ME--(Marketwired - February 10, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results
Read more →ICCCImmuCell Announces Full Year 2015 Financial Results Q4 Sales up 22%; Full Year Sales up 35%; Q4 Diluted EPS: $0.09 vs. $0.04; Full Year Diluted EPS: $0.38 vs. $(0.06) PORTLAND, ME -- (Marketwired
ImmuCell Announces Full Year 2015 Financial Results Q4 Sales up 22%; Full Year Sales up 35%; Q4 Diluted EPS: $0.09 vs. $0.04; Full Year Diluted EPS: $0.38 vs. $(0.06) PORTLAND, ME -- (Marketwired - February 10, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal healt
Read more →ICCCImmuCell to Announce 2015 Financial Results
PORTLAND, ME--(Marketwired - February 04, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, will report financial results for
Read more →ICCCImmuCell Corporation Announces Closing of $5.9 Million Public Offering of Common Stock
PORTLAND, ME--(Marketwired - February 03, 2016) - ImmuCell Corporation ("ImmuCell" or the "Company") (NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today annou
Read more →ICCCImmuCell Corporation Announces Closing of $5.9 Million Public Offering of Common Stock PORTLAND, ME -- (Marketwired
ImmuCell Corporation Announces Closing of $5.9 Million Public Offering of Common Stock PORTLAND, ME -- (Marketwired - February 03, 2016) - ImmuCell Corporation ("ImmuCell" or the "Company") (NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling pr
Read more →ICCC: ImmuCell Corporation Announces Pricing of $5.9 Million Public Offering of Common Shares Contact: Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and
Corporation Announces Pricing of $5.9 Million Public Offering of Common Shares Contact: Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com PORTLAND, Mai
Read more →ICCCImmuCell Corporation Announces Pricing of $5.9 Million Public Offering of Common Shares
PORTLAND, ME--(Marketwired - January 29, 2016) - ImmuCell Corporation ("ImmuCell" or the "Company") (NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announc
Read more →ICCCImmuCell Corporation Announces Proposed Public Offering of Common Stock and Preliminary Full Year 2015 Results PORTLAND, ME -- (Marketwired
ImmuCell Corporation Announces Proposed Public Offering of Common Stock and Preliminary Full Year 2015 Results PORTLAND, ME -- (Marketwired - January 28, 2016) - ImmuCell Corporation ("ImmuCell" or the "Company") (NASDAQ: ICCC), an animal health company that is developing, manuf
Read more →ICCCImmuCell Corporation Announces Proposed Public Offering of Common Stock and Preliminary Full Year 2015 Results
PORTLAND, ME--(Marketwired - January 28, 2016) - ImmuCell Corporation ("ImmuCell" or the "Company") (NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announ
Read more →ICCC: ImmuCell Acquires Certain Assets from Minnesota Firm Contact: Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (60
FOR IMMEDIATE RELEASE: Acquires Certain Assets from Minnesota Firm Contact: Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com PORTLAND, Maine - Januar
Read more →ICCCImmuCell Acquires Certain Assets From Minnesota Firm
PORTLAND, ME--(Marketwired - January 06, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a rapidly growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced that it ha
Read more →ICCCImmuCell Enters Into New Contract With Norbrook
PORTLAND, ME--(Marketwired - December 22, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced that it has
Read more →ICCCPRODUCT DEVELOPMENT & CONTRACT MANUFACTURE AGREEMENT THIS AGREEMENT is dated 17 th of December 2015. PARTIES IMMUCELL CORPORATION, a corporation duly organised and existing under the laws of the State of Delaware, United
& CONTRACT MANUFACTURE AGREEMENT THIS AGREEMENT is dated 17th IMMUCELL CORPORATION, a corporation duly organised and existing under the laws of the State of Delaware, United States of America (USA) having its principal office at 56 Evergreen Drive, Portland, Maine, USA ("IMMU
Read more →ICCCImmuCell Announces Results for Third Quarter of 2015
PORTLAND, ME--(Marketwired - November 12, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial re
Read more →ICCCImmuCell Announces Results for Third Quarter of 2015 Total Sales Increase 40% During Third Quarter and First Nine Months; EPS of $0.11 and $0.29 During Three-Month and Nine-Month Periods Ended
ImmuCell Announces Results for Third Quarter of 2015 Total Sales Increase 40% During Third Quarter and First Nine Months; EPS of $0.11 and $0.29 During Three-Month and Nine-Month Periods Ended September 30, 2015, Respectively PORTLAND, ME -- (Marketwired - November 12, 2015) -
Read more →ICCCImmuCell to Announce Third Quarter 2015 Financial Results
PORTLAND, ME--(Marketwired - November 05, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report third quarter of
Read more →ICCCAmended and Restated Loan Agreement This Agreement is entered into this 21 st day of September, 2015 by, between and among ImmuCell Corporation (the " Borrower ") and TD Bank, N.A . (together with its successors and assi
and Restated Loan Agreement Agreement is entered into this 21st day of September, 2015 by, between and among ImmuCell Corporation (the "Borrower") and TD Bank, N.A. (together with its successors and assigns, the "Lender"), for itself and as agent for any Affiliate Counterparty
Read more →ICCCImmuCell Announces Results for Second Quarter of 2015
PORTLAND, ME--(Marketwired - August 13, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial resu
Read more →ICCCIMMUCELL CORPORATION PRESS RELEASE ImmuCell Announces Results for Second Quarter of 2015 Total Sales During Second Quarter Increase 27%; Sales of First Defense(R) During Second Quarter Increase 25%; EPS of $0.03 and $0.1
IMMUCELL CORPORATION PRESS RELEASE ImmuCell Announces Results for Second Quarter of 2015 Total Sales During Second Quarter Increase 27%; Sales of First Defense(R) During Second Quarter Increase 25%; EPS of $0.03 and $0.18 During Three-Month and Six-Month Periods Ended June 30,
Read more →ICCCImmuCell to Announce Second Quarter 2015 Financial Results
PORTLAND, ME--(Marketwired - August 06, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report second quarter of
Read more →ICCCImmuCell Corp. Increases Sales Guidance for Second Quarter of 2015
PORTLAND, ME--(Marketwired - July 08, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced an improvement i
Read more →ICCCIMMUCELL CORPORATION PRESS RELEASE ImmuCell Corp. Increases Sales Guidance for Second Quarter of 2015 PORTLAND, ME -- (Marketwired
IMMUCELL CORPORATION PRESS RELEASE ImmuCell Corp. Increases Sales Guidance for Second Quarter of 2015 PORTLAND, ME -- (Marketwired - July 08, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that
Read more →ICCCImmuCell Announces Results for First Quarter of 2015
PORTLAND, ME--(Marketwired - May 12, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results
Read more →ICCCImmuCell Announces Results for First Quarter of 2015 Total Sales During First Quarter Increase 49%; Sales of First Defense(R) During First Quarter Increase 62%; Investing in Company-Owned Facility to Meet G
ImmuCell Announces Results for First Quarter of 2015 Total Sales During First Quarter Increase 49%; Sales of First Defense(R) During First Quarter Increase 62%; Investing in Company-Owned Facility to Meet Growing Sales Demand PORTLAND, ME -- (Marketwired - May 12, 2015) - ImmuC
Read more →ICCCImmuCell to Announce First Quarter 2015 Financial Results
PORTLAND, ME--(Marketwired - May 06, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report first quarter of 2015
Read more →ICCCImmuCell Board of Directors Amends Its Common Stock Rights Plan PORTLAND, ME -- (Marketwired
ImmuCell Board of Directors Amends Its Common Stock Rights Plan PORTLAND, ME -- (Marketwired - April 15, 2015) - ImmuCell Corporation (NASDAQ: ICCC) today announced that its Board of Directors has voted to amend its Common Stock Rights Plan (Rights Plan). The Rights Plan was fi
Read more →ICCCImmuCell Board of Directors Amends Its Common Stock Rights Plan
PORTLAND, ME--(Marketwired - April 15, 2015) - ImmuCell Corporation (NASDAQ: ICCC) today announced that its Board of Directors has voted to amend its Common Stock Rights Plan (Rights Plan). The Rights Plan was first implemented in 1995 and has been amended and extended several t
Read more →ICCCImmuCell Announces New Bacteriocin Collaboration With the University of Massachusetts Amherst
PORTLAND, ME--(Marketwired - April 14, 2015) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it has entered into an exclusive option agreement to license new bacteriocin technology from the University of Massachusetts Amherst. This technology, developed by Dr. Margare
Read more →ICCCImmuCell Reports Results From Rotavirus Pivotal Effectiveness Study
PORTLAND, ME--(Marketwired - Feb 25, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced positive results
Read more →ICCCImmuCell Announces Financial Results for 2014
PORTLAND, ME--(Marketwired - Feb 11, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results
Read more →ICCCImmuCell to Announce 2014 Full Year and Fourth Quarter Financial Results
PORTLAND, ME--(Marketwired - Feb 4, 2015) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report 2014 full year and fou
Read more →ICCCImmuCell to Present at LD Micro Conference on December 2, 2014
PORTLAND, ME--(Marketwired - Nov 25, 2014) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that Michael Brig
Read more →ICCCImmuCell Announces Financial Results for Third Quarter of 2014
PORTLAND, ME--(Marketwired - Nov 12, 2014) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results
Read more →ICCCImmuCell to Announce Third Quarter Fiscal Year 2014 Financial Results
PORTLAND, ME--(Marketwired - Nov 3, 2014) - ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report financial results for i
Read more →ICCCImmuCell Participating at Multiple Dairy and Beef Industry Events Throughout September 2014
PORTLAND, ME--(Marketwired - Sep 17, 2014) - ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it will be pa
Read more →ICCCImmuCell Announces Financial Results for the Second Quarter of 2014
PORTLAND, ME--(Marketwired - Aug 12, 2014) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results
Read more →ICCCImmuCell Initiates Pivotal Effectiveness Study to Prevent Calf Scours Caused by Rotavirus
PORTLAND, ME--(Marketwired - Jul 15, 2014) - ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has commen
Read more →ICCCImmuCell Commences Manufacture of Nisin Necessary for Approval of Mast Out(R)
PORTLAND, ME--(Marketwired - Jul 9, 2014) - ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has complet
Read more →ICCCImmuCell NasdaqCM: ICCC Corporate Presentation May 2014 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E o
ImmuCell NasdaqCM: ICCC Corporate Presentation May 2014 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements incl
Read more →ICCCImmuCell Announces Results for the First Quarter of 2014
PORTLAND, ME--(Marketwired - May 13, 2014) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results
Read more →ICCCImmuCell Retains Lytham Partners to Conduct National Investor Relations Program
PORTLAND, ME--(Marketwired - Apr 10, 2014) - ImmuCell Corporation (NASDAQ: ICCC), an emerging animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has ret
Read more →ICCCImmuCell Announces Increase in Product Sales and Other Annual Financial Results
PORTLAND, ME--(Marketwired - Feb 13, 2014) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013. During the three-month period ended December 31, 2013, product sales increased by
Read more →ICCCImmuCell Announces Increased Product Sales and Continued Profitability
PORTLAND, ME--(Marketwired - Nov 12, 2013) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and nine-month periods ended September 30, 2013. During the three-month period ended September 30, 2013, product sales increased by
Read more →ICCCImmuCell Announces Increase in Product Sales and Continued Profitability
PORTLAND, ME--(Marketwired - Aug 12, 2013) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2013. During the three-month period ended June 30, 2013, product sales increased by 16%, or $19
Read more →ICCCImmuCell Suspends Mast Out(R) Partnering Effort; Pursuit of FDA Product Approval to Continue
PORTLAND, ME--(Marketwired - Jul 18, 2013) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it has suspended its active pursuit of a partner for Mast Out , its Nisin-based intramammary mastitis treatment product under development for dairy cows. ImmuCell has presented
Read more →ICCCImmuCell Announces Product Sales Increases and Other Financial Results
PORTLAND, ME--(Marketwire - Feb 14, 2013) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2012. "Despite the ongoing economic hardships faced by our customers, we ended the year w
Read more →ICCCImmuCell Presents Strategic Business Overview at Investment Forum
PORTLAND, ME--(Marketwire - Aug 28, 2012) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it has been selected to present a business overview at the 2012 Kansas City Animal Health Investment Forum in Kansas City, Missouri. "We are engaged in ongoing discussions relate
Read more →ICCCImmuCell Announces Profitable Financial Results
PORTLAND, ME--(Marketwire - Aug 13, 2012) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2012. "Based primarily on increased gross margin from sales of First Defense and the planned red
Read more →ICCCImmuCell Receives Effectiveness Technical Section Complete Letter From FDA for Mast Out(R)
PORTLAND, ME--(Marketwire - Jul 19, 2012) - ImmuCell Corporation (NASDAQ: ICCC) announced today that it received a Technical Section Complete Letter from the FDA relating to its Effectiveness Technical Section submission for Mast Out , its Nisin-based intramammary treatment of su
Read more →ICCCImmuCell Presents Strategic Overview at Annual Meeting of Stockholders
PORTLAND, ME--(Marketwire - Jun 19, 2012) - ImmuCell Corporation (NASDAQ: ICCC) announced today that it presented a strategic overview of the Company's business at its Annual Meeting of Stockholders on June 14, 2012 and has today posted this information on the Investor Relations
Read more →ICCCImmuCell Announces Product Sales Growth and Profit
PORTLAND, ME--(Marketwire - May 14, 2012) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended March 31, 2012. During the three-month period ended March 31, 2012, product sales increased by 10%, or $161,000, to $1,7
Read more →ICCCImmuCell Announces Product Sales Growth and Other Financial Results for 2011
PORTLAND, ME--(Marketwire - Feb 13, 2012) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2011. During the three-month period ended December 31, 2011, product sales increased by 1
Read more →ICCCImmuCell Presents Mast Out(R) Product Offering at World Animal Health Congress PORTLAND, ME -- (Marketwire
ImmuCell Presents Mast Out(R) Product Offering at World Animal Health Congress PORTLAND, ME -- (Marketwire - December 08, 2011) - ImmuCell Corporation (NASDAQ: ICCC) is today presenting its Mast Out product offering at the World Animal Health Congress at the Intercontinental Hot
Read more →ICCCImmuCell Announces Product Sales Growth and Other Financial Results for Third Quarter of 2011
PORTLAND, ME--(Marketwire - Nov 14, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and nine-month periods ended September 30, 2011. During the three-month period ended September 30, 2011, product sales increased by 1
Read more →ICCCImmuCell appoints David S. Cunningham to Board of Directors
ImmuCell appoints David S. Cunningham to Board of Directors PORTLAND, Maine - September 7, 2011 -- ImmuCell Corporation (NASDAQ: ICCC) today announced that Mr. David S. Cunningham was appointed to serve on the Company's Board of Directors. Mr. Cunningham is President and CEO of
Read more →ICCCImmuCell Announces Product Sales Growth and Other Financial Results for Second Quarter of 2011
PORTLAND, ME--(Marketwire - Aug 15, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2011. During the three-month period ended June 30, 2011, product sales increased by 16%, or $170
Read more →ICCCImmuCell Comments on Status of Zero Milk Discard Claim for Mast Out PORTLAND, ME--(Marketwire
ImmuCell Comments on Status of Zero Milk Discard Claim for Mast Out PORTLAND, ME--(Marketwire - Jun 9, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced that the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA) has accepted the pivotal Nisin resi
Read more →ICCCImmuCell Announces Financial Results for First Quarter of 2011
PORTLAND, ME--(Marketwire - May 16, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter ended March 31, For the three-month period ended March 31, 2011, product sales increased by 19%, or $244,000, to $1,556,000 in comparis
Read more →ICCCImmuCell Announces Sales and Marketing Collaboration With AgriLabs
PORTLAND, ME--(Marketwire - March 17, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it has entered into a sales and marketing collaboration with Agri Laboratories Ltd. of St. Joseph, Missouri. The AgriLabs sales and marketing teams will work with ImmuCell to e
Read more →ICCCImmuCell Receives Effectiveness Technical Section Incomplete Letter From FDA
PORTLAND, ME--(Marketwire - February 16, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it received an Effectiveness Technical Section Incomplete Letter from the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA). "While this is a setback t
Read more →ICCCIMMUCELL
IMMUCELL RECEIVES EFFECTIVENESS TECHNICAL SECTION INCOMPLETE LETTER FROM FDA PORTLAND, Maine - February 16, 2011 -- ImmuCell Corporation (NASDAQ: ICCC) today announced that it received an Effectiveness Technical Section Incomplete Letter from the Center for Veterinary Medicine,
Read more →ICCCImmuCell Announces Financial Results for 2010
PORTLAND, ME--(Marketwire - February 9, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter and year ended For the three-month period ended December 31, 2010, product sales increased by 9%, or $89,000, to $1,123,000 in comp
Read more →ICCCRobert C. Bruce c/o Oakmont Advisory Group 477 Congress Street Portland, Maine 04102 Tel: 207-553-2177 Via Email
c/o Oakmont Advisory Group Portland, Maine 04102 Joseph H. Crabb, Ph.D. Chairman of the Board of Directors Re: Resignation from the Immucell Board of Directors I am writing to tender my resignation from the Board of Directors of Immucell Corporation (the Company ), effectiv
Read more →ICCCImmuCell Announces Financial Results for Third Quarter of 2010
PORTLAND, ME--(Marketwire - November 8, 2010) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and nine-month periods ended September 30, 2010. "We sold our 10,000,000th dose of First Defense during the third quarter. Thi
Read more →ICCCImmuCell Announces Financial Results for Second Quarter of 2010
PORTLAND, ME--(Marketwire - August 5, 2010) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2010. For the three-month period ended June 30, 2010, product sales increased by 8%, or $77,00
Read more →ICCCImmuCell Announces Financial Results for First Quarter of 2010
PORTLAND, ME--(Marketwire - May 6, 2010) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter ended March 31, 2010. For the three-month period ended March 31, 2010, product sales decreased by 10%, or $149,000, to $1,312,000 in compa
Read more →ICCCImmuCell Announces Financial Results for 2009
PORTLAND, ME--(Marketwire - February 10, 2010) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter and year ended For the three-month period ended December 31, 2009, product sales decreased by 17%, or $213,000, to $1,034,000 in c
Read more →ICCCImmuCell Hires Director of Sales and Marketing
PORTLAND, ME--(Marketwire - January 4, 2010) - ImmuCell Corporation (NASDAQ: ICCC) today announced the hiring of Bobbi Jo Kunde as Director of Sales and Marketing. Ms. Kunde is a graduate of Iowa State University. After several positions with advertising and marketing firms, s
Read more →ICCCImmuCell Announces Financial Results for Third Quarter of 2009
PORTLAND, ME--(Marketwire - November 4, 2009) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter and nine months ended September 30, 2009. For the three-month period ended September 30, 2009, product sales increased by 9%, or $
Read more →ICCCImmuCell's Mastitis Drug Meets Pivotal Effectiveness Study End Point
PORTLAND, ME--(Marketwire - September 30, 2009) - ImmuCell Corporation (NASDAQ: ICCC) today announced initial results from its pivotal effectiveness study of Mast Out . All data, results and conclusions discussed in this press release are subject to review and approval by the
Read more →ICCCImmuCell Announces Financial Results for Second Quarter of 2009
PORTLAND, ME--(Marketwire - August 4, 2009) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter and six months ended June 30, 2009. For the three-month period ended June 30, 2009, product sales increased by 21%, or $175,000, to
Read more →ICCCImmuCell Announces Financial Results for First Quarter of 2009
PORTLAND, ME--(Marketwire - May 5, 2009) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended For the three-month period ended March 31, 2009, product sales decreased by 10%, or $171,000, to $1,460,000 in comparis
Read more →ICCCImmuCell Announces Financial Results for 2008
PORTLAND, ME--(Marketwire - February 11, 2009) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter and year ended For the three-month period ended December 31, 2008, product sales decreased by 16%, or $243,000, to $1,247,000 in c
Read more →ICCCImmuCell Announces Financial Results for Third Quarter
PORTLAND, ME--(Marketwire - November 4, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three and nine-month periods ended September 30, 2008. For the three-month period ended September 30, 2008, product sales decreased by 6%,
Read more →ICCCImmuCell Announces Financial Results for the First Half of 2008
PORTLAND, ME--(Marketwire - August 4, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three and six month periods ended June 30, 2008. For the three-month period ended June 30, 2008, product sales increased by 4%, or $35,000,
Read more →ICCCImmuCell Initiates Pivotal Trial of Mast Out(R)
PORTLAND, ME--(Marketwire - June 5, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it has initiated the pivotal effectiveness field trial of Planning and preparations for this trial began in July 2007. Completion of the field trial is expected by year-end. En
Read more →ICCCImmuCell Announces Financial Results for First Quarter of 2008
PORTLAND, ME--(Marketwire - May 5, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended For the three-month period ended March 31, 2008, product sales increased by 8%, or $122,000, to $1,631,000 in compariso
Read more →ICCCImmuCell Announces Cross-License With Anadis
PORTLAND, ME--(Marketwire - March 12, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it had entered into a cross-license of technology with Anadis Limited (ASX: ANX) of Australia. ImmuCell granted Anadis an exclusive, worldwide license to the human and envir
Read more →ICCCImmuCell Announces Financial Results for 2007
PORTLAND, ME--(Marketwire - February 7, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three and twelve month periods ended December 31, 2007. For the three-month period ended December 31, 2007, product sales increased by 41%
Read more →ICCCImmuCell Announces Financial Results for Third Quarter of 2007
PORTLAND, ME--(Marketwire - November 2, 2007) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three and nine month periods ended September 30, 2007. For the three month period ended September 30, 2007, product sales decreased by 7%,
Read more →ICCCImmuCell Announces Financial Results for Second Quarter Of 2007
PORTLAND, ME--(Marketwire - August 3, 2007) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three and six month periods ended June 30, 2007. For the three months ended June 30, 2007, product sales were $791,000, representing an incr
Read more →ICCCImmuCell Announces Termination of Mast Out(R) License and Return of All Rights and Data From Pfizer
PORTLAND, ME--(Marketwire - July 19, 2007) - ImmuCell Corporation (NASDAQ: ICCC) today announced that Pfizer Animal Health has elected to terminate its product development and marketing agreement covering Mast Out . "We appreciate the advances that Pfizer has made in the devel
Read more →ICCCImmuCell Announces Financial Results for First Quarter of 2007
PORTLAND, ME -- (MARKET WIRE) -- April 19, 2007 -- ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended For the three months ended March 31, 2007, product sales were $1,509,000, representing an increase of $71,000,
Read more →ICCCImmuCell Announces Financial Results for Fourth Quarter and Full Year 2006
PORTLAND, ME -- (MARKET WIRE) -- February 7, 2007 -- ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three and twelve month periods ended December 31, 2006. For the three months ended December 31, 2006, product sales were $1,060,000 r
Read more →ICCCImmuCell Appoints Two New Directors to Board
PORTLAND, ME -- (MARKET WIRE) -- December 21, 2006 -- ImmuCell Corporation (NASDAQ: ICCC) today announced that Mr. Robert C. Bruce and Dr. David S. Tomsche have been appointed to serve on the Company's Board of Directors. Mr. Bruce is the founder, owner and president of Oakmon
Read more →ICCCImmuCell Announces Financial Results for Third Quarter and First Nine Months of 2006
PORTLAND, ME -- (MARKET WIRE) -- October 19, 2006 -- ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three and nine month periods ended September 30, 2006. For the three months ended September 30, 2006, product sales increased by 35%,
Read more →ICCC: Contact: Michael F. Brigham
FOR IMMEDIATE RELEASE : Contact: Michael F. Brigham August 22, 2005 President and Chief Executive Officer (207) 878-2770 Ext. 3106 ALCHERABIO JOINS BOARD OF IMMUCELL PORTLAND, Maine August 22, 2005 ImmuCell Corporation (NASDAQ: ICCC) today announced that Linda Rhodes,
Read more →Competitive Position
How ICCC ranks across every disease it competes inCompetitive Position is a premium feature
See how ICCC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial